Richmond Pharmacology is pleased to attend the Decarbonising Life Sciences conference in London on 25 November 2025, hosted by Health Industry Leaders.


This meeting brings together senior stakeholders and policymakers to address how the life sciences sector can accelerate progress toward national net-zero goals through sustainable manufacturing, greener supply chains, and evidence-driven policy.


Our ESG Commitment

  • Environmental Responsibility, Social Empowerment, and Strong Governance.
  • Reducing environmental impact across procurement, operations, travel, and facilities.
  • Strengthening responsible supply chains and promoting sustainable manufacturing.
  • Using recognised frameworks (Ecovadis, SBTi, CDP) to measure and report environmental performance.
  • Supporting our diverse workforce and local communities through volunteering, education partnerships, and social initiatives.
  • Upholding the highest standards of patient safety, employee safety, and ethical governance.

Representing Richmond Pharmacology:


Our Focus at the Conference

  • Sustainable medicines manufacturing and low-carbon supply chains
  • Policy frameworks enabling net-zero in health and life sciences
  • Waste reduction, recyclability, and emissions minimisation
  • Cross-sector collaboration between the NHS, regulators, and industry
  • Data and technology solutions to measure environmental impact


Connect With Us

If you are attending Decarbonising Life Sciences 2025 and would like to explore sustainability or development partnership opportunities:


📧 info@richmondpharmacology.com

Latest news

Richmond Pharmacology Welcomes Back Dr Edward Jackson as Medical Director

November 3, 2025
Richmond Pharmacology is pleased to announce the return of Dr Edward Jackson, who re-joins the organisation as Medical Director.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event